SCHEMBL2554910

SCHEMBL2554910

CC(C)N(C(C)C)P(OCl)OCCC#N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL383731 0.89 TSHR (0.32)
SCHEMBL4818972 0.87 TSHR (0.31)
SCHEMBL16504168 0.85 TSHR (0.30)
SCHEMBL2621446 0.85 TSHR (0.30)
SCHEMBL14136628 0.85 TSHR (0.30)
SCHEMBL23139033 0.82
SCHEMBL10030503 0.82 TSHR (0.35)
SCHEMBL21395330 0.82 TSHR (0.31)
SCHEMBL19364625 0.82
SCHEMBL23823738 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304613-A1 AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE CONJUGATION APPROACH ALNYLAM PHARMACEUTICALS, INC. (US) 2025-10-02 US disclosed
US-20250207131-A1 MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT ALNYLAM PHARMACEUTICALS, INC. (US) 2025-06-26 US disclosed
US-12275938-B2 Modified RNA agents with reduced off-target effect ALNYLAM PHARMACEUTICALS, INC. (US) 2025-04-15 US disclosed
US-12247203-B2 Modified RNA agents with reduced off-target effect ALNYLAM PHARMACEUTICALS, INC. 2025-03-11 US disclosed
EP-4367125-A1 AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH Alnylam Pharmaceuticals, Inc. (US) 2024-05-15 EP disclosed
WO-2023283434-A9 AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH ALNYLAM PHARMACEUTICALS, INC. (US) 2024-03-28 WO disclosed
WO-2023283434-A1 AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH ALNYLAM PHARMACEUTICALS, INC. (US) 2023-01-12 WO disclosed
US-20220290145-A1 Modified RNA Agents with Reduced Off-Target Effect ALNYLAM PHARMACEUTICALS, INC. (US) 2022-09-15 US disclosed
US-20210238595-A1 MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT ALNYLAM PHARMACEUTICALS, INC. (US) 2021-08-05 US disclosed
US-10131908-B2 5′ phosphate mimics ALNYLAM PHARMACEUTICALS, INC. (US) 2018-11-20 US disclosed
US-5824796-A MEDICAL DIAGNOSIS WITH TARGET DNA OR RNA FOR ENZYME INHIBITORS EPOCH PHARMACEUTICALS, INC. (US) 1998-10-20 US disclosed
EP-0637314-B1 N-ACYLATED 2'-DEOXYCYTIDINES USEFUL IN OLIGONUCLEOTIDE SYNTHESIS BECKMAN INSTRUMENTS INC (US) 1998-06-24 EP disclosed
EP-0843684-A2 UNIVERSAL SOLID SUPPORTS AND METHODS FOR THEIR USE BECKMAN INSTRUMENTS, INC. (US) 1998-05-27 EP disclosed
US-5726301-A ADDITION OF DEOXYCYTIDINE FOR OLIGONUCLEOTIDES BECKMAN INSTRUMENTS, INC. (US) 1998-03-10 US disclosed
WO-1997040458-A2 UNIVERSAL SOLID SUPPORTS AND METHODS FOR THEIR USE BECKMAN INSTRUMENTS, INC. (US) 1997-10-30 WO disclosed
US-5623068-A Synthesis of DNA using substituted phenylacetyl-protected nucleotides BECKMAN INSTRUMENTS, INC. (US) 1997-04-22 US disclosed
US-5616700-A GENETIC ENGINEERING BECKMAN INSTRUMENTS, INC. (US) 1997-04-01 US disclosed
EP-0749436-A1 COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES BECKMAN INSTRUMENTS, INC. (US) 1996-12-27 EP disclosed
WO-1995024413-A1 COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES BECKMAN INSTRUMENTS, INC. (US) 1995-09-14 WO disclosed
US-5428148-A Reduced side product formation BECKMAN INSTRUMENTS, INC. (US) 1995-06-27 US disclosed